--- title: "深圳市美好创亿医疗科技股份有限公司 (301363.SZ)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/301363.SZ.md" symbol: "301363.SZ" name: "深圳市美好创亿医疗科技股份有限公司" industry: "医疗器械" --- # 深圳市美好创亿医疗科技股份有限公司 (301363.SZ) | Item | Detail | |------|--------| | Industry | 医疗器械 | | Location | 沪深市场 | | Website | [www.mehow.com](https://www.mehow.com) | ## Company Profile 公司是全球领先的医疗器械研发及生产服务提供商。为医疗器械产业提供科研转化及生产制造平台 (CDMO)、承接医疗器械注册人制度 (MAH) 下各类医疗器械研发和生产服务。公司主要从事医疗器械精密组件及产品的设计开发、制造和销售,为全球医疗器械企业提供从产品研发到批量交付的全流程一站式服务,致力于成为全球卓越的医疗科技服务商。公司主要产品为家用呼吸机组件、人工植入耳蜗组件、精密模具及自动化设备、肺功能仪等。公司荣誉:“国家知识产权优势企业”、“广东省制造业单项冠军” 等荣誉称号。 ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-18T04:30:10.000Z **Overall: B (0.33)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 6 / 63 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 12.49% | | | Net Profit YoY | 15.88% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 5.36 | | | Dividend Ratio | 0.43% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 19.84B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 1.63B | | **Multi Score**: B #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 8.86% | B | | Profit Margin | 19.25% | A | | Gross Margin | 44.24% | B | #### Growth Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 12.49% | B | | Net Profit YoY | 15.88% | B | | Total Assets YoY | 10.68% | B | | Net Assets YoY | 9.26% | B | #### Cash Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 519.57% | C | | OCF YoY | 12.49% | B | #### Operating Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.41 | C | #### Debt Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 11.43% | A | ```chart-data:radar { "title": "Longbridge Financial Score - 深圳市美好创亿医疗科技股份有限公司", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "8.86%", "rating": "B" }, { "name": "Profit Margin", "value": "19.25%", "rating": "A" }, { "name": "Gross Margin", "value": "44.24%", "rating": "B" } ] }, { "name": "Growth", "grade": "B", "indicators": [ { "name": "Revenue YoY", "value": "12.49%", "rating": "B" }, { "name": "Net Profit YoY", "value": "15.88%", "rating": "B" }, { "name": "Total Assets YoY", "value": "10.68%", "rating": "B" }, { "name": "Net Assets YoY", "value": "9.26%", "rating": "B" } ] }, { "name": "Cash", "grade": "B", "indicators": [ { "name": "Cash Flow Margin", "value": "519.57%", "rating": "C" }, { "name": "OCF YoY", "value": "12.49%", "rating": "B" } ] }, { "name": "Operating", "grade": "C", "indicators": [ { "name": "Turnover", "value": "0.41", "rating": "C" } ] }, { "name": "Security", "grade": "A", "indicators": [ { "name": "Gearing Ratio", "value": "11.43%", "rating": "A" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | 联影医疗 (SH.688271) | B | B | C | B | B | B | | 02 | 鱼跃医疗 (SZ.002223) | B | B | C | A | C | B | | 03 | 惠泰医疗 (SH.688617) | A | B | B | A | B | B | | 04 | 奕瑞科技 (SH.688301) | A | B | E | A | B | B | | 05 | 振德医疗 (SH.603301) | C | B | C | B | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 63.17 | 33/66 | 46.11 | 40.17 | 28.98 | | PB | 5.36 | 54/66 | 3.96 | 3.38 | 2.93 | | PS (TTM) | 12.16 | 49/66 | 8.79 | 7.74 | 6.44 | | Dividend Yield | 0.43% | 43/66 | 0.63% | 0.42% | 0.32% | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-07T16:00:00.000Z Total Analysts: **3** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 3 | 100% | | Overweight | 0 | 0% | | Hold | 0 | 0% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 34.88 | | Highest Target | 28.00 | | Lowest Target | 27.11 | ## References - [Company Overview](https://longbridge.com/en/quote/301363.SZ/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/301363.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/301363.SZ/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.